- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04417270
Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In hospitalized patients diagnosed with COVID-19, diabetes mellitus is associated with a higher mortality. Patients with controlled blood glucose have a lower mortality rate than those who are uncontrolled. However, a rigid blood glucose control - which may lead to hypoglycemia- is associated with higher mortality rates. Thus, adequate glucose monitoring is important for hospitalized diabetic patients.
Previous studies have shown that CGMS, in the outpatient setting, engender better glycemic control thereby reducing risk of hypoglycemia. CGMS offer a replacement for finger stick blood glucose monitoring which may not identify an incidence of hypoglycemia until symptoms drive the patient to test. Furthermore, finger stick blood glucose monitoring is painful and time consuming thus causing many patients to avoid this aspect of diabetes self-care management.
Freestyle Libre CGMs sample interstitial fluid glucose subcutaneously. Measurement frequencies typically range from 1 to 15 minutes and most commonly are every 5 minutes.
Previous studies in hospitalized patients living with diabetes mellitus on basal bolus regimen have shown:
• Use of the CGM increased detection of both hypoglycemic and hyperglycemic events versus those sensed by POCT.
One investigation identified 88 postprandial hyperglycemic excursions in patients with CGM use as opposed to 61 in those with POCT. Another noted that when comparing the CGM use with that of POCT, the former identified 55 hypoglycemic events whereas the latter only found 12.
• No difference in mean daily glucose CGM and POCT readings. In a study of 38 patients, the investigators noted no difference in mean daily glucose between the CGM and POCT.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10022
- Lenox Hill Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants acquired from among all non-critical care in patients who are living with Diabetes Mellitus. Because the patients will have to be instructed on the use of the CGM, this study will be limited to English speaking/reading adults (18 years of age or older), who possess the cognitive and physical ability to participate.
Exclusion Criteria:
- Minors, pregnant women, and critically ill.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Freestyle Libre 14-day CGM
The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
|
The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care.
Wireless meter quickly transfers data.
The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
|
Annen: Accuchek Inform II meter
ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
|
The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care.
Wireless meter quickly transfers data.
The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Comparison of values between two devices
Tidsramme: Through end of patient hospitalization, an average of 14 days
|
Correlation between blood glucose results from the Freestlye Libre 14-day CGM and Accuchek Inform II platform using the Bland-Altman method to determine whether the two glucose methods agree
|
Through end of patient hospitalization, an average of 14 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Renee Murray-Bachmann, Ed.D, MSN, Northwell Health
Publikasjoner og nyttige lenker
Hjelpsomme linker
- Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: A Multicenter, Open-Label Randomize
- Zhu, L., Zhi-Gang, S., Cheng, S., Guo, J., Bing-Hong, Z.,Hongliang, L. (2020).Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 Diabetes Cell Metabolism, 31, (2020).pp.1-10
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 20-0455
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sukkersyke
-
Medical College of WisconsinMedical University of South CarolinaFullførtSukkersyke | Type 2 diabetes mellitus | Voksendiabetes mellitus | Ikke-insulinavhengig diabetes mellitus | Ikke-insulinavhengig diabetes mellitus, type IIForente stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinavhengig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | Diabetes mellitus, sprø | Diabetes mellitus... og andre forholdForente stater
-
SanofiFullførtType 1 Diabetes Mellitus-Type 2 Diabetes MellitusUngarn, Den russiske føderasjonen, Tyskland, Polen, Japan, Forente stater, Finland
-
Meir Medical CenterFullførtDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, om oral hypoglykemisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkjentType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskapsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestasjonell diabetes mellitus | Diabetespasienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Legemiddelindusert diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsFullførtDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
University of California, San FranciscoJuvenile Diabetes Research FoundationFullførtType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | IDDMForente stater, Australia
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater